The news, released after the market close Friday, gave a big boost to Amgen investors, who have been looking anxiously at the RANK ligand inhibitor to help the company gain back ground lost by its safety-plagued ESA franchise. Top-line data from the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every Six Months) trial showed that denosumab, given as a subcutaneous injection, resulted in a statistically significant reduction in the incidence of new vertebral fractures compared to placebo, the primary endpoint. (BioWorld Today) Read More
